Found 7 matching trials
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
PHASE2The purpose of this study is to establish a prospective, single-center plat...
Location
Fudan University Shanghai Cancer Center Shanghai, China, 200032
Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
PHASE2This study aims to investigate the safety and efficacy of combination thera...
Location
Fudan university shanghai cancer center, Deparment of gynecologic oncology
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
PHASE2The purpose of this study is to establish a prospective, multi-center platf...
Location
Breast cancer institute of Fudan University Cancer Hospital
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
PHASE2This study is a prospective, open-label, phase II clinical study for patien...
Location
Breast cancer institute of Fudan University Cancer Hospital
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
PHASE3This study is a prospective, open-label, phase III clinical study for patie...
Status
Active Not Recruiting
Location
breast cancer institute of Fudan University Cancer Hospital
Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma
PHASE2This is a single-center, single-arm phase Ib / II clinical trial, which was...
Location
Cancer Center of Sun-Yat Sen University (CCSYSU)
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
PHASE1This study is an open-label, multicenter, Phase Ib/II clinical study to eva...
Location
Henan Provincial Cancer Hospital